Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Recruiting now · Phase 1
Conditions studied: Hepatic Impairment, Moderate Hepatic Impairment
In brief
The primary purpose of this study is to evaluate the plasma PK of zanzalintinib following a single dose in participants with moderate liver dysfunction compared to matched healthy participants with normal liver function.
Key facts
- Study ID
- NCT06962332
- Run by
- Exelixis
- People needed
- 20
- Starts
- 2025-05-13
- Expected to finish
- 2026-04-01
- Last updated by the study team
- 2025-06-22
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Exelixis Clinical Site #1 — Orlando, Florida, United States (enrolling)
- Exelixis Clinical Site #2 — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.